Zydus announces Phase I trials of ZYIL1, oral small molecule NLRP3 inflammasome inhibitor
NLRP3 inflammasomes lead to the onset and development of diseases like ARDS, auto-immune diseases, inflammatory diseases, CVDs,…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.